Loading
A phase 1/2 trial of Directional Brachytherapy Source Implant in pancreatic ductal adenocarcinoma, run by CivaTech Oncology, now recruiting.
Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source is a phase 1/2 interventional study registered as NCT02843945 by CivaTech Oncology, with 80 participants planned, started 2017-05-31 and due to reach its primary completion in 2027-10-29. Interventions recorded: Directional Brachytherapy Source Implant.
Shares CivaTech Oncology and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.